Searched for
BIOCON LTD NEWS
West Bengal's electronics factory push; Fed jitters hit TCSWest Bengal is exploring ways to expand electronics manufacturing under EMC 2.0. This and more in today's ETtech Top 5.- Ahead of Market: 10 things that will decide stock market action on WednesdayDomestic equity benchmarks ended lower on Tuesday, snapping a three-session rally amid profit booking in financial, realty and consumer sto...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Stocks in news: BSE, Britannia, Paytm, Meesho, RILIndian markets showed resilience, climbing despite volatility, buoyed by positive global trends and falling crude oil prices. Analysts anti...
- Stocks in news: Paytm, Bajaj Auto, L&T, Bharti Airtel, Hero MotoCorpMarkets closed lower amid global headwinds and geopolitical worries. Several companies like Paytm, Bajaj Auto, and L&T are in focus due to ...
- Claire Mazumdar: A silent force behind a $1.6 billion firm may write Biocon's future scriptsBiocon founder Kiran Mazumdar-Shaw has named her niece, Claire Mazumdar, as her successor. Claire Mazumdar, a successful CEO of Bicara Ther...
- Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What's driving the surge?Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...
- Stocks in news: TCS, HDFC Bank, ITC Hotels, Hyundai India, Adani EnterprisesMarkets surged for the fourth consecutive session, buoyed by favorable geopolitical cues. Key stocks like TCS, HDFC Bank, ITC Hotels, Hyund...
- Biocon sees GLP-1 weight-loss therapy as a future growth driverBiocon will strengthen its insulin business while advancing in GLP-1 therapies, with semaglutide in Phase-III trials and a planned 2027 Ind...
- Biocon launches diabetes, obesity management drug in UKBiocon has launched Liraglutide, a drug for diabetes and obesity management, in the UK under the brand names Liraglutide Biocon and Biolide...
- Biocon Biologics mulls raising up to Rs 4,500 crore in bondsThe company is in discussions with banks for the issuance, the people said, asking not to be named because the details are private. Funds f...
- Biocon drops 4% as USFDA issues form 483 for 3 sitesAs per the US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when an in...
- Hold Biocon, target price Rs 380: ICICI DirectBiocon, incorporated in the year 1978, is a Large Cap company (having a market cap of Rs 44314.15 crore) operating in Pharmaceuticals secto...
- Viatris deal pinches Biocon, but may prove a good betThe $3.3-billion acquisition - that includes $2.3 billion cash and a 12.9% equity stake in BBL - stands at over half of the market cap of B...
- Biocon Q3 Results: Net profit rises 11% YoY to Rs 187 croreThe earnings before interest, tax depreciation and amortisation (EBITDA) rose 25% YoY to Rs 537 crore. The EBITDA margins for the third qua...
- R&D will continue to dive Biocon run: Gaurang ShahR&D could put pressure on the cash flows at least in the short to medium term but over a longer period of time we do remain positive on Bio...
- Biocon to stay buoyant going forward: Mehraboon IraniBullish on Biocon, recommend it even now before a dip: Mehraboon Irani.
- GE capital picks up 7.69% in Biocon's Syngene for Rs 125 croreThe total valuation of Syngene with this investment stands at Rs 1600 cr. Following the news, Biocon shares jumped by over 3%.
- Buy Biocon on dips: Anu Jain"I would probably keep holding that and use the dips to buy into it so there is no denying that that’s a good buy on any dips."
- Biocon can move up another 6% to 8%: Ambareesh BaligaThose who have been holding on to this stock for a long time, it has been a bit of a underperformer if you see in the last 1-1.5 years. So ...
Load More
